Selection of vasodilator, inotropic or combined therapy for the management of heart failure

Jay N Cohn, Joseph A. Franciosa

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Vasodilator and inotropic drugs work through independent mechanisms in augmenting left ventricular pump function in patients with heart failure. The selection between these two classes of pharmacologic agents for an individual patient may be based on the control blood pressure as well as the underlying disease. Although vasodilator drugs are easiest and safest to employ in patients with normal or high arterial pressure levels, even in relatively hypotenslve subjects (systolic arterial pressure less than 105 mm Hg), a salutary hemodynamic effect can be achieved without an undue decrease in pressure. Inotropic drugs may be safest to administer to patients without coronary artery disease, but the oxygen-consuming effect of these drugs need not necessarily have an adverse effect on patients with ischemic heart disease. Combined vasodilator and inotropic drug therapy is the most potent pharmacologic means of restoring pump function in patients with severe heart failure. The long-term use of vasodilator and inotropic drugs in the treatment of heart failure is dependent on the availability of agents that will produce a sustained hemodynamic effect. Hydralazine, nitrates and prazosin have been employed alone or in combination and provide a promising approach to vasodilator treatment of heart failure. Better and more selective oral inotropic agents are needed to allow this therapeutic modality to be employed optimally.

Original languageEnglish (US)
Pages (from-to)181-188
Number of pages8
JournalThe American journal of medicine
Volume65
Issue number1
DOIs
StatePublished - Jan 1 1978

Fingerprint

Vasodilator Agents
Heart Failure
Treatment Failure
Arterial Pressure
Hemodynamics
Blood Pressure
Therapeutics
Hydralazine
Prazosin
Proxy
Left Ventricular Function
Pharmaceutical Preparations
Nitrates
Myocardial Ischemia
Coronary Artery Disease
Oxygen
Pressure
Drug Therapy

Cite this

Selection of vasodilator, inotropic or combined therapy for the management of heart failure. / Cohn, Jay N; Franciosa, Joseph A.

In: The American journal of medicine, Vol. 65, No. 1, 01.01.1978, p. 181-188.

Research output: Contribution to journalArticle

@article{7dde82cfcf774bebb8124c13317db8b0,
title = "Selection of vasodilator, inotropic or combined therapy for the management of heart failure",
abstract = "Vasodilator and inotropic drugs work through independent mechanisms in augmenting left ventricular pump function in patients with heart failure. The selection between these two classes of pharmacologic agents for an individual patient may be based on the control blood pressure as well as the underlying disease. Although vasodilator drugs are easiest and safest to employ in patients with normal or high arterial pressure levels, even in relatively hypotenslve subjects (systolic arterial pressure less than 105 mm Hg), a salutary hemodynamic effect can be achieved without an undue decrease in pressure. Inotropic drugs may be safest to administer to patients without coronary artery disease, but the oxygen-consuming effect of these drugs need not necessarily have an adverse effect on patients with ischemic heart disease. Combined vasodilator and inotropic drug therapy is the most potent pharmacologic means of restoring pump function in patients with severe heart failure. The long-term use of vasodilator and inotropic drugs in the treatment of heart failure is dependent on the availability of agents that will produce a sustained hemodynamic effect. Hydralazine, nitrates and prazosin have been employed alone or in combination and provide a promising approach to vasodilator treatment of heart failure. Better and more selective oral inotropic agents are needed to allow this therapeutic modality to be employed optimally.",
author = "Cohn, {Jay N} and Franciosa, {Joseph A.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1016/0002-9343(78)90708-8",
language = "English (US)",
volume = "65",
pages = "181--188",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Selection of vasodilator, inotropic or combined therapy for the management of heart failure

AU - Cohn, Jay N

AU - Franciosa, Joseph A.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - Vasodilator and inotropic drugs work through independent mechanisms in augmenting left ventricular pump function in patients with heart failure. The selection between these two classes of pharmacologic agents for an individual patient may be based on the control blood pressure as well as the underlying disease. Although vasodilator drugs are easiest and safest to employ in patients with normal or high arterial pressure levels, even in relatively hypotenslve subjects (systolic arterial pressure less than 105 mm Hg), a salutary hemodynamic effect can be achieved without an undue decrease in pressure. Inotropic drugs may be safest to administer to patients without coronary artery disease, but the oxygen-consuming effect of these drugs need not necessarily have an adverse effect on patients with ischemic heart disease. Combined vasodilator and inotropic drug therapy is the most potent pharmacologic means of restoring pump function in patients with severe heart failure. The long-term use of vasodilator and inotropic drugs in the treatment of heart failure is dependent on the availability of agents that will produce a sustained hemodynamic effect. Hydralazine, nitrates and prazosin have been employed alone or in combination and provide a promising approach to vasodilator treatment of heart failure. Better and more selective oral inotropic agents are needed to allow this therapeutic modality to be employed optimally.

AB - Vasodilator and inotropic drugs work through independent mechanisms in augmenting left ventricular pump function in patients with heart failure. The selection between these two classes of pharmacologic agents for an individual patient may be based on the control blood pressure as well as the underlying disease. Although vasodilator drugs are easiest and safest to employ in patients with normal or high arterial pressure levels, even in relatively hypotenslve subjects (systolic arterial pressure less than 105 mm Hg), a salutary hemodynamic effect can be achieved without an undue decrease in pressure. Inotropic drugs may be safest to administer to patients without coronary artery disease, but the oxygen-consuming effect of these drugs need not necessarily have an adverse effect on patients with ischemic heart disease. Combined vasodilator and inotropic drug therapy is the most potent pharmacologic means of restoring pump function in patients with severe heart failure. The long-term use of vasodilator and inotropic drugs in the treatment of heart failure is dependent on the availability of agents that will produce a sustained hemodynamic effect. Hydralazine, nitrates and prazosin have been employed alone or in combination and provide a promising approach to vasodilator treatment of heart failure. Better and more selective oral inotropic agents are needed to allow this therapeutic modality to be employed optimally.

UR - http://www.scopus.com/inward/record.url?scp=0018132382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018132382&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(78)90708-8

DO - 10.1016/0002-9343(78)90708-8

M3 - Article

C2 - 685992

AN - SCOPUS:0018132382

VL - 65

SP - 181

EP - 188

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -